The Crusade against Mutant p53: Does the COMPASS Point to the Holy Grail?
- PMID: 26461087
- DOI: 10.1016/j.ccell.2015.09.019
The Crusade against Mutant p53: Does the COMPASS Point to the Holy Grail?
Abstract
Mutations in the TP53 gene not only inactivate its tumor suppressor function but also confer this transcription factor with gain-of-function oncogenic properties. A recent paper by Zhu and colleagues reveals a novel molecular pathway driven by mutant p53 and the COMPASS chromatin-modifying complex that is amenable to pharmacological inhibition.
Copyright © 2015 Elsevier Inc. All rights reserved.
Comment on
-
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.Nature. 2015 Sep 10;525(7568):206-11. doi: 10.1038/nature15251. Epub 2015 Sep 2. Nature. 2015. PMID: 26331536 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
